Video

David Fabrizio Explores Complexities of Surrogate Endpoints in Cancer Clinical Trials

The FDA has been willing to explore the utilization of surrogate endpoints like tumor response in clinical trials, but it is unclear whether these endpoints correlate with overall survival, said David Fabrizio of Foundation Medicine, Inc. However, he emphasized that overall survival does not necessarily benefit the patient if the additional days gained are not quality days.

The FDA has been willing to explore the utilization of surrogate endpoints like tumor response in clinical trials, but it is unclear whether these endpoints correlate with overall survival, said David Fabrizio of Foundation Medicine, Inc. However, he emphasized that overall survival does not necessarily benefit the patient if the additional days gained are not quality days.

Transcript (slightly modified)

How will the FDA and payers respond to having alternate endpoints in cancer clinical trials?

I think that the FDA has done a good job, as evidenced by their willingness to utilize these surrogate endpoints across a number of trials. We heard Dr. Khozin, one of my panelists [at Patient-Centered Oncology Care], speak about the adoption of looking at tumor response, a tumor shrinking versus growing, so I think that there is a willingness there and I think there’s certainly an open mind to exploring these additional options.

I think the challenge on us is whether or not these actually correlate with overall survival in the end. Of course, once you start going down that road, there’s the question of whether this truly does add benefit to a patient’s life. It’s one thing to simply add days to survival, it’s another thing to add quality days to that survival too, so that’s a completely different discussion.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Dan Nardi
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo